BMPR-II; Bone Morphogenetic Protein Receptor Type-2; BMP Type-2 Receptor; BMPR-2; Bone Morphogenetic Protein Receptor Type II; BMP Type II Receptor; BMPR-II; BMPR2; PPH1

For Research Use Only. Not for use in diagnostic procedures.

Human Cells

> 95% by SDS-PAGE.

Lyophilized from a 0.2 muM filtered solution of 20mM PB, 150mM NaCl, pH 7.4.

Store the lyophilized protein at-20 degree C to-80 degree C for long term.
After reconstitution, the protein solution is stable at-20 degree C for 3 months, at 2-8 degree C for up to 1 week.

Small volumes of BMPR-II recombinant protein vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Recombinant Human BMPR-II/PPH1/BMPR2 Protein is produced by human cells expression system. The target protein is expressed with sequence (Ser27-Ile151) of human BMPR-II/PPH1/BMPR2 (Accession #Q13873) fused with an Fc, 6xHis tag at the C-terminus.

Recombinant Human BMPR-II/PPH1/BMPR2 Protein was determined by SDS-PAGE under reducing conditions with Coomassie Blue.

59,963 Da

bone morphogenetic protein receptor type 2

bone morphogenetic protein receptor type-2

Bone morphogenetic protein receptor type-2

PPH1; BMP type-2 receptor; BMPR-2; BMP type II receptor; BMPR-II??[Similar Products]

This gene encodes a member of the bone morphogenetic protein (BMP) receptor family of transmembrane serine/threonine kinases. The ligands of this receptor are BMPs, which are members of the TGF-beta superfamily. BMPs are involved in endochondral bone formation and embryogenesis. These proteins transduce their signals through the formation of heteromeric complexes of two different types of serine (threonine) kinase receptors: type I receptors of about 50-55 kD and type II receptors of about 70-80 kD. Type II receptors bind ligands in the absence of type I receptors, but they require their respective type I receptors for signaling, whereas type I receptors require their respective type II receptors for ligand binding. Mutations in this gene have been associated with primary pulmonary hypertension, both familial and fenfluramine-associated, and with pulmonary venoocclusive disease. [provided by RefSeq, Jul 2008]

On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Binds to BMP7, BMP2 and, less efficiently, BMP4. Binding is weak but enhanced by the presence of type I receptors for BMPs. Mediates induction of adipogenesis by GDF6.

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.